Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.37 |
| ▸ | TUBB | P07437 | 3/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.37 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.37 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.37 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.37 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.37 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.37 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.37 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.37 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774887 | 0.81 | CYP19A1 (0.40) | ALDH1A1LMNASMN1; SMN2HPGDNPC1 | |
| SCHEMBL5772173 | 0.81 | TDO2 (0.55) | TDO2ALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL10205956 | 0.80 | TDO2 (0.39) | TDO2ALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL5775970 | 0.78 | TDO2 (0.51) | TDO2ALDH1A1HPGDNOTUMPTPN1 | |
| SCHEMBL5775812 | 0.78 | CYP19A1 (0.34) | LMNANPC1RAB9AMAPK1CYP2C19 | |
| SCHEMBL5775635 | 0.78 | MEN1 (0.39) | LMNASMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL27350305 | 0.77 | TDO2 (0.39) | TDO2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5773828 | 0.77 | NR4A2 (0.47) | TDO2ALDH1A1LMNAHPGDMAPK1 | |
| SCHEMBL5776248 | 0.75 | TDO2 (0.45) | TDO2ALDH1A1NOTUMPTPN1NR4A2 | |
| SCHEMBL5774472 | 0.74 | RXRA (0.50) | ALDH1A1LMNAHPGDMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951793-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1656368-A4 | SUBSTITUTED HERTOCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7279485-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1656368-A2 | SUBSTITUTED HERTOCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004004665-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
| US-4256480-A | Isoxazolyl-alkyl thiocarbamates and herbicidal compositions thereof | PHILAGRO (FR) | 1981-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | PYM1, GPR119, GLP1R | TDO2 1935/4885ALDH1A1 4235/4885LMNA 161/4885 |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | GPR119, SLC5A2, GLP1R | TDO2 1624/4885ALDH1A1 3824/4885LMNA 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.